BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis

@article{Pochon2010BR55AL,
  title={BR55: A Lipopeptide-Based VEGFR2-Targeted Ultrasound Contrast Agent for Molecular Imaging of Angiogenesis},
  author={S. Pochon and I. Tardy and P. Bussat and T. Bettinger and J. Brochot and M. V. von Wronski and L. Passantino and M. Schneider},
  journal={Investigative Radiology},
  year={2010},
  volume={45},
  pages={89-95}
}
  • S. Pochon, I. Tardy, +5 authors M. Schneider
  • Published 2010
  • Chemistry, Medicine
  • Investigative Radiology
    • Objectives:BR55, an ultrasound contrast agent functionalized with a heterodimer peptide targeting the vascular endothelial growth factor receptor 2 (VEGFR2), was evaluated in vitro and in vivo, demonstrating its potential for specific tumor detection. Materials and Methods:The targeted contrast agent was prepared by incorporation of a biospecific lipopeptide into the microbubble membrane. Experiments were performed in vitro to demonstrate the binding capacities of BR55 microbubbles on… CONTINUE READING
    View on Wolters Kluwer
    ncbi.nlm.nih.gov
    228 Citations
    Highly Influencial Citations
    6
    Background Citations
    62
    Methods Citations
    23
    Results Citations
    3
    228 Citations
    Citation Type

    Citation Type

    A Lipopeptide-Based αvβ₃ Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis.
    • 22
    Ultrasound Molecular Imaging of the Breast Cancer Neovasculature using Engineered Fibronectin Scaffold Ligands: A Novel Class of Targeted Contrast Ultrasound Agent
    • 30
    • PDF
    Ultrasound Molecular Imaging of VEGFR2 in a Rat Prostate Tumor Model Using BR55
    • 112
    Ultrasound molecular imaging of tumor angiogenesis with a neuropilin-1-targeted microbubble.
    • 38
    VEGFR2-Targeted Contrast-Enhanced Ultrasound to Distinguish between Two Anti-Angiogenic Treatments.
    • 17
    • PDF
    Targeted contrast-enhanced ultrasound imaging of angiogenesis in an orthotopic mouse tumor model of renal carcinoma.
    • 36
    Quantitative ultrasound molecular imaging by modeling the binding kinetics of targeted contrast agent.
    • 14
    Targeted Antiangiogenesis Gene Therapy Using Targeted Cationic Microbubbles Conjugated with CD105 Antibody Compared with Untargeted Cationic and Neutral Microbubbles
    • 42
    • PDF
    Sensitive Angiogenesis Imaging of Orthotopic Bladder Tumors in Mice Using a Selective Magnetic Resonance Imaging Contrast Agent Containing VEGF121/rGel
    • 30
    Squamous Cell Carcinoma Xenografts: Use of VEGFR2-targeted Microbubbles for Combined Functional and Molecular US to Monitor Antiangiogenic Therapy Effects.
    • 30

    References

    SHOWING 1-10 OF 33 REFERENCES
    US imaging of tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice.
    • 280
    Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects
    • 157
    • PDF
    Relationship Between Retention of a Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)‐Targeted Ultrasonographic Contrast Agent and the Level of VEGFR2 Expression in an In Vivo Breast Cancer Model
    • 80
    Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo.
    • 178
    Pharmacodynamics of Streptavidin-Coated Cyanoacrylate Microbubbles Designed for Molecular Ultrasound Imaging
    • 52
    Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis
    • 120
    Monitoring Response to Anticancer Therapy by Targeting Microbubbles to Tumor Vasculature
    • 241
    • PDF
    A Molecular Imaging Paradigm to Rapidly Profile Response to Angiogenesis-directed Therapy in Small Animals
    • 20
    Targeting vascular endothelium with avidin microbubbles.
    • 91
    In vivo ultrasound imaging of thrombi using a target-specific contrast agent.
    • 21